Diabetes, Hypoglycemia
Conditions
Keywords
Diabetic, Diabetes, Type 1 Diabetes, Type 1 Diabetes Mellitus, autoimmune disease
Brief summary
The purpose of this study is to determine the safety of BHT-3021 injections given weekly for 12 weeks and to evaluate the effect of BHT-3021 on antibody and immune (T cell) responses to autoantigens (e.g. insulin). Changes in pancreatic beta cell function, insulin requirements and blood glucose levels will also be evaluated.
Detailed description
Type 1 diabetes results from an attack by the body's own immune system on the insulin producing cells in the pancreas. Around 80% of diagnosed patients have detectable antibodies to islet cell self-proteins including, insulin IA-2 and glutamic acid decarboxylase. The drug, BHT-3021 is being studied because an agent that stops autoimmune damage could offer patients benefit. Study Description: A Randomized, Blinded, Placebo Controlled, Safety and Pharmacodynamic Study of BHT-3021 with Open Label Cross-Over in Subjects with Type I Diabetes Mellitus that will enroll up to 72 subjects in this trial. Subjects will be randomized to BHT-3021 or BHT-placebo in a 2:1 ratio. The duration of the study is approximately 25 to 37 months depending on treatment assignment: 4 week Screening Period; 12 month Blinded Treatment and Evaluation Period; 12 month Cross-over Treatment and Evaluation Period (BHT-placebo subjects only); 12 month Long Term Follow-Up period.
Interventions
DRUGBHT-3021
Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
DRUGBHT-Placebo
Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
Sponsors
Bayhill Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Type 1a Diabetes Mellitus based on ADA Criteria * ≤5 years since T1D was diagnosed * ≥ 18 years of age * ≤ 40 years of age at the time of diagnosis of Type 1a diabetes * Presence of antibodies to at least one of the following antigens: insulin, GAD-65, or IA-2 * Detectable fasting C-peptide level * C-peptide increase during screening mixed meal tolerance test with a minimal stimulated value of ≥ 0.2 pmol/mL * Presence of antibodies to at least one of the following antigens: insulin, GAD-65, or IA-2. If insulin antibody positive only, determination must be within 2 weeks of insulin initiation
Exclusion criteria
* BMI \> 30 kg/m2 * Unstable blood sugar control defined as one or more episodes of severe hypoglycemia (defined as hypoglycemia that required the assistance of another person) within the last 30 days * Current use of inhalable insulin * Previous immunotherapy for T1D * Administration of an experimental agent for T1D at any time or use of an experimental device for T1D within 30 days prior to screening, unless approved by the medical monitor * History of any organ transplant, including islet cell transplant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint in this study is safety.Safety parameters include: stimulated C-peptide response levels, opthalmologic examination, laboratory assessments, 24-hr urine protein, allergic reactions and adverse events including hypoglycemia. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints are pharmacodynamic parameters. Parameters include plasmid levels and insulin mRNA levels in blood and urine, Stimulated C-peptide response and Immunological response. | — |
Countries
Australia, New Zealand, United States
Outcome results
None listed